Pharvaris, a Phase 1 biotech developing oral small molecule therapies for rare diseases, raised $165 million by offering 8.3 million shares at $20, above the range of $17 to $19. The company sold 19% more shares than originally anticipated.
The Netherlands-based biotech, which has offices in the US and Switzerland, plans to list on the Nasdaq under the symbol PHVS. Morgan Stanley, BofA Securities and SVB Leerink acted as lead managers on the deal.
